



Unifying the care experience

For personal use only

APPENDIX 4E  
PRELIMINARY FINAL  
REPORT  
YEAR ENDED  
31 DECEMBER 2022

For personal use only



**Appendix 4E**  
**Preliminary Final Report**  
**Oneview Healthcare PLC**  
**ABN 610 611 768**

**1. Company Details**

Name of Entity

**Oneview Healthcare PLC**

ABN or equivalent  
company reference

**610 611 768**

Financial year ended  
(current period)

**31 December 2022**

Financial year ended  
(previous period)

**31 December 2021**

**2. Results for announcement to the market**

	Up/down	% change	31 December 2022 €'000	31 December 2021 €'000
Recurring revenue from ordinary activities	Up	16%	6,185	5,351
Total revenue from ordinary activities	Down	8%	8,921	9,732
(Loss) from ordinary activities after tax attributable to members (including significant items)	Up	33%	(10,869)	(8,185)
(Loss) from ordinary activities after tax attributable to members (excluding significant items *)	Up	16%	(7,815)	(6,732)

\* Significant items incurred include FX and non-cash share based payments.

**3. Net Tangible Assets Per Security**

	31 December 2022 €	31 December 2021 €
Net Tangible Assets Per Security	0.004	0.02

Net tangible assets are defined as the net assets of Oneview Healthcare PLC less intangible assets. A small proportion of the Company's assets are intangible in nature. These assets are excluded from the calculation of net tangible assets per security shown above.

For personal use only

#### **4. Commentary on Results**

The principal activity of the Group is the development and sale of software for the healthcare sector and the provision of related consultancy services.

The directors report that revenue for the year from continuing operations amounted to €8,921,499 (2021: €9,731,894), a decrease of 8%. Recurring revenue for the year amounted to €6,185,160 (2021: €5,351,346), an increase of 16% and continues to grow as the company deploys across its customer base.

As at 31 December 2022, the Oneview solution was live in 10,139 beds with a further 4,336 beds contracted but not yet installed.

#### **5. Dividends**

The Company has not declared, and does not propose to pay, any dividends for the year ended 31 December 2022 (31 December 2021: Nil). There are no dividend or dividend reinvestment plans in operation.

#### **6. Details of entities over which control has been gained or lost during the period**

There are no entities over which control has been gained or lost in the period.

#### **7. Associates and joint venture entities**

There are no associate or joint venture entities.

#### **8. Audit status**

This Appendix 4E and the included financial information are based on financial statements which have not been audited, but are in the process of being audited.

#### **9. Foreign entity accounting standards**

The Financial Statements contained within the Preliminary Final Report are measured and recognised in accordance with International Financial Reporting Standards, as adopted by the European Union.

#### **10. Financial Report**

The following financial report included in this Appendix 4E does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and operating, financial and investing activities of the consolidated entity as the full annual financial report. This financial report should be read in conjunction with any public announcements made by Oneview Healthcare PLC in accordance with the continuous disclosure obligations of the ASX Listing Rules.

The accounting policies are the same as those applied in the most recent interim financial report and the previous annual report.

## Consolidated Statement of Total Comprehensive Income

for the year ended 31 December 2022

		2022 Unaudited	2021 Audited
	Note	€	€
<b>Revenue</b> - continuing operations	2	<b>8,921,499</b>	9,731,894
Cost of sales		<b>(3,575,857)</b>	(4,424,129)
<b>Gross profit</b>		<b>5,345,642</b>	5,307,765
Other income	3	<b>1,360,637</b>	-
Sales and marketing expenses		<b>(3,918,579)</b>	(2,278,120)
Product development and delivery expenses		<b>(10,070,026)</b>	(7,856,186)
General and administrative expenses		<b>(3,543,075)</b>	(3,303,455)
<b>Operating loss</b>		<b>(10,825,401)</b>	(8,129,996)
Finance charges		<b>(162,459)</b>	(118,617)
Finance income		<b>63,180</b>	120,317
<b>Loss before tax</b>		<b>(10,924,680)</b>	(8,128,296)
Income tax		<b>55,221</b>	(56,723)
<b>Loss for the year</b>		<b>(10,869,459)</b>	(8,185,019)
<b>Attributable to ordinary shareholders</b>		<b>(10,869,459)</b>	(8,185,019)
<i>Loss per share</i>			
Basic	4	<b>(0.02)</b>	(0.02)
Diluted	4	<b>(0.02)</b>	(0.02)
<b>Other comprehensive loss</b>			
<i>Items that will or may be reclassified to profit or loss:</i>			
Foreign currency translation differences on foreign operations (no tax impact)		<b>(80,260)</b>	(172,958)
Other comprehensive loss, net of tax		<b>(80,260)</b>	(172,958)
<b>Total comprehensive loss for the year</b>		<b>(10,949,719)</b>	(8,357,977)

The total comprehensive loss for the year is entirely attributable to equity holders of the Group.

## Consolidated Statement of Financial Position as at 31 December 2022

		2022 Unaudited	2021 Audited
	Note	€	€
<b>Non-current assets</b>			
Intangible assets	5	264,877	478,767
Property, plant and equipment	6	613,779	1,282,885
Research and development tax credit	7	639,639	603,526
<b>Total non-current assets</b>		<b>1,518,295</b>	2,365,178
<b>Current assets</b>			
Inventories		1,227,691	686,079
Trade and other receivables	7	3,342,163	2,538,334
Contract assets		240,035	309,466
Current income tax receivable		16,025	12,374
Cash and cash equivalents		6,409,936	15,175,985
<b>Total current assets</b>		<b>11,235,850</b>	18,722,238
<b>Total assets</b>		<b>12,754,145</b>	21,087,416
<b>Equity</b>			
Issued share capital	10	534,990	518,477
Share premium	10	120,369,325	120,071,867
Treasury reserve		(2,586)	(2,586)
Other undenominated capital		4,200	4,200
Translation reserve		13,994	94,254
Reorganisation reserve		(1,351,842)	(1,351,842)
Share based payments reserve		6,446,943	4,344,439
Retained earnings		(123,758,477)	(113,778,692)
<b>Total equity</b>		<b>2,256,547</b>	9,900,117
<b>Non-current liabilities</b>			
Trade and other payables	9	2,789,637	-
Lease liabilities		370,732	838,007
Deferred income		20,295	54,564
<b>Total non-current liabilities</b>		<b>3,180,664</b>	892,571
<b>Current liabilities</b>			
Trade and other payables	8	7,144,655	9,886,584
Lease liabilities		172,279	366,690
Current income tax liabilities		-	41,454
<b>Total current liabilities</b>		<b>7,316,934</b>	10,294,728
<b>Total liabilities</b>		<b>10,497,598</b>	11,187,299
<b>Total equity and liabilities</b>		<b>12,754,145</b>	21,087,416

For personal use only

## Consolidated Statement of Cash Flows

for the year ended 31 December 2022

		2022	2021
		Unaudited	Audited
	Note	€	€
<b>Cash flows from operating activities</b>			
Receipts from customers		8,838,970	11,688,222
Legal claim settlement proceeds		1,360,637	-
Payments to employees and suppliers		(19,609,240)	(16,111,455)
Finance charges paid		(104,932)	(118,617)
Interest received		570	87
Research and development tax credit received		621,561	638,258
Income tax paid		(17,647)	(123,290)
<b>Net cash used in operating activities</b>	11	<b>(8,910,081)</b>	<b>(4,026,795)</b>
<b>Cash flows from investing activities</b>			
Purchase of property, plant and equipment	6	(44,518)	(65,263)
<b>Net cash used in investing activities</b>		<b>(44,518)</b>	<b>(65,263)</b>
<b>Cash flows from financing activities</b>			
Proceeds from issue of shares		309,458	13,377,421
Transaction costs		(91,640)	(871,446)
Repayment of lease liabilities		(317,925)	(287,032)
<b>Net cash (used in)/provided by financing activities</b>		<b>(100,107)</b>	<b>12,218,943</b>
Net (decrease)/ increase in cash held		<b>(9,054,706)</b>	8,126,885
Foreign exchange impact on cash and cash equivalents		288,657	244,733
Cash and cash equivalents at beginning of financial year		15,175,985	6,804,367
<b>Cash and cash equivalents at end of financial year</b>		<b>6,409,936</b>	15,175,985

For personal use only

## Consolidated Statement of Changes in Equity

as at 31 December 2022

	Share capital	Share premium	Treasury reserve	Other undenominated capital	Reorganisation reserve	Share based payments reserve	Translation reserve	Retained loss	Total equity
	€	€	€	€	€	€	€	€	€
<b>Balance at 1 January 2021</b>	<b>394,589</b>	<b>106,785,298</b>	<b>(2,586)</b>	<b>4,200</b>	<b>(1,351,842)</b>	<b>3,813,324</b>	<b>267,212</b>	<b>(105,841,482)</b>	<b>4,068,713</b>
Loss for the year	-	-	-	-	-	-	-	(8,185,019)	(8,185,019)
Foreign currency translation	-	-	-	-	-	-	(172,958)	-	(172,958)
<b>Total comprehensive loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(172,958)</b>	<b>(8,185,019)</b>	<b>(8,357,977)</b>
<i>Transactions with shareholders</i>									
Issue of ordinary shares	90,741	13,268,842	-	-	-	-	-	(692,905)	12,666,678
Share based compensation to employees	-	-	-	-	-	1,242,982	-	-	1,242,982
Share based compensation to non-employees	-	-	-	-	-	330,641	-	(68,758)	261,883
Vesting of restricted share unit awards	26,786	-	-	-	-	(775,353)	-	748,567	-
Exercise of share options	111	17,727	-	-	-	(4,267)	-	4,267	17,838
Vesting of share awards	6,250	-	-	-	-	(242,030)	-	235,780	-
Transfer to retained earnings in respect of expired options	-	-	-	-	-	(20,858)	-	20,858	-
<b>As at 31 December 2021</b>	<b>518,477</b>	<b>120,071,867</b>	<b>(2,586)</b>	<b>4,200</b>	<b>(1,351,842)</b>	<b>4,344,439</b>	<b>94,254</b>	<b>(113,778,692)</b>	<b>9,900,117</b>



## Consolidated Statement of Changes in Equity (continued)

as at 31 December 2022

	Share capital	Share premium	Treasury reserve	Other undenominated capital	Reorganisation reserve	Share based payments reserve	Translation reserve	Retained loss	Total equity
	€	€	€	€	€	€	€	€	€
<b>Balance at 1 January 2022</b>	<b>518,477</b>	<b>120,071,867</b>	<b>(2,586)</b>	<b>4,200</b>	<b>(1,351,842)</b>	<b>4,344,439</b>	<b>94,254</b>	<b>(113,778,692)</b>	<b>9,900,117</b>
Loss for the year	-	-	-	-	-	-	-	(10,869,459)	(10,869,459)
Foreign currency translation	-	-	-	-	-	-	(80,260)	-	(80,260)
<b>Total comprehensive loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(80,260)</b>	<b>(10,869,459)</b>	<b>(10,949,719)</b>
<i>Transactions with shareholders</i>									
Exercise of share options	12,000	297,458	-	-	-	(68,758)	-	68,758	309,458
Share based compensation to employees	-	-	-	-	-	2,996,691	-	-	2,996,691
Vesting of restricted share unit awards	4,513	-	-	-	-	(609,773)	-	605,260	-
Transfer to retained earnings in respect of expired restricted share unit awards	-	-	-	-	-	(215,135)	-	215,135	-
Transfer to retained earnings in respect of expired options	-	-	-	-	-	(521)	-	521	-
<b>As at 31 December 2022</b>	<b>534,990</b>	<b>120,369,325</b>	<b>(2,586)</b>	<b>4,200</b>	<b>(1,351,842)</b>	<b>6,446,943</b>	<b>13,994</b>	<b>(123,758,477)</b>	<b>2,256,547</b>

## **1. Statement of Significant Accounting Policies**

### **Statement of compliance**

This report is not a set of statutory financial statements and does not include all the information required for a complete set of financial statements, prepared in accordance with IFRS as adopted by the European Union. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since 31 December 2021. They should be read in conjunction with the statutory consolidated financial statements of the Group, which were prepared in accordance with IFRS as adopted by the European Union, as at and for the year ended 31 December 2021 and also in conjunction with any public announcements made by Oneview Healthcare PLC during the year.

### **Going Concern**

The Group's financial statements have been prepared and presented on a going concern basis.

This report adopts the going concern basis of accounting, which contemplates the realisation of assets and the discharge of liabilities and commitments in the ordinary course of business.

During the prior year, the Company successfully conducted placements which raised A\$21 million (€13.4m) before costs. The Company has an extensive sales pipeline, of which several opportunities are expected to be contracted in the coming months. The Group has implemented a number of cash management initiatives, aiming to improve cash flow for the Group, which most recently included a headcount reduction and a downsizing of its office space and associated costs. Accordingly, the Directors believe the business has adequate levels of working capital to fund the Group's strategic goals. They believe, therefore, that the Group continues to be a going concern and that it will be able to pay its debts as and when they fall due, for a period of at least 12 months from the date of this report.

On this basis, the Directors believe that the going concern basis of presentation is appropriate. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Group not have the ability to continue as a going concern. If for any reason the Group is unable to continue as a going concern, it would impact on the Group's ability to realise assets at their recognised values and to extinguish liabilities in the normal course of business at the amounts stated in the consolidated financial statements.

### **Use of estimates and judgments**

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected. In preparing this financial report, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation and uncertainty were the same as those that apply to the consolidated financial statements for the year ended 31 December 2021.

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2022

**2. Revenue**

**Revenue by type**

**Recurring revenue:**

	<b>2022</b>	2021
	<b>Unaudited</b>	Audited
	€	€
Software usage and content	<b>3,978,661</b>	3,389,226
Support income	<b>2,055,044</b>	1,723,197
Licence fee	<b>151,455</b>	238,923
	<b>6,185,160</b>	5,351,346

**Non-recurring revenue:**

Hardware	<b>1,701,684</b>	3,463,178
Services income	<b>1,034,655</b>	917,370
	<b>2,736,339</b>	4,380,548

**Total revenue**

<b>8,921,499</b>	9,731,894
------------------	-----------

**Revenue attributable to geographic region:**

	<b>2022</b>	2021
	<b>Unaudited</b>	Audited
	€	€
Ireland	<b>4,200</b>	4,659
United States	<b>5,679,550</b>	4,489,627
Australia	<b>2,864,910</b>	4,695,919
Asia	<b>279,128</b>	398,335
Middle East and North Africa	<b>93,711</b>	143,354

**Total revenue**

<b>8,921,499</b>	9,731,894
------------------	-----------

**3. Other income**

The other income in the current year relates to a commercial settlement agreed with aged care operator Regis Aged Care Pty Ltd in relation to the claim launched by the Company for breach of the Collaboration Agreement between the parties without admission of liability of either party. A settlement of A\$2 million (€1.36 million) was agreed and was received by the Company in May 2022. Legal fees of €0.07 million associated with the claim were incurred and paid during the period and are reflected in professional and legal fees within general and administrative costs.

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2022

**4. Earnings per share**

	<b>2022</b> <b>Unaudited</b> €	2021 Audited €
<b>Basic earnings per share</b>		
Loss attributable to ordinary shareholders	<b>(10,869,459)</b>	(8,185,019)
Weighted average number of ordinary shares outstanding (i)	<b>522,319,679</b>	431,345,276
<b>Basic loss per share</b>	<b>(0.02)</b>	(0.02)

	<b>2022</b> <b>No.</b>	2021 No.
<b>(i) Weighted-average number of ordinary shares (basic)</b>		
Issued ordinary shares at 1 January	<b>518,477,053</b>	394,588,636
Effect of shares issued	<b>3,842,626</b>	36,756,640
Weighted average number of ordinary shares at 31 December	<b>522,319,679</b>	431,345,276

Basic loss per share is calculated by dividing the loss for the year after taxation attributable to ordinary shareholders by the weighted average number of ordinary shares in issue during the year.

	<b>2022</b> <b>Unaudited</b> €	2021 Audited €
<b>Diluted earnings per share</b>		
Loss attributable to ordinary shareholders	<b>(10,869,459)</b>	(8,185,019)
Weighted average number of ordinary shares outstanding (i)	<b>522,319,679</b>	431,345,276
<b>Diluted loss per share</b>	<b>(0.02)</b>	(0.02)

For personal use only

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2022

**4. Earnings per share (continued)**

	<b>2022</b>	2021
	<b>No.</b>	No.
<b>(ii) Weighted-average number of ordinary shares (diluted)</b>		
Issued ordinary shares at 1 January	<b>518,477,053</b>	394,588,636
Effect of shares issued	<b>3,842,626</b>	36,756,640
Weighted average number of ordinary shares at 31 December	<b><u>522,319,679</u></b>	<u>431,345,276</u>

The calculation of diluted earnings per share has been based on the loss attributable to ordinary shareholders and weighted average number of ordinary shares outstanding after adjustments for the effects of all dilutive ordinary shares. Potential ordinary shares are treated as dilutive when, and only when, their conversion to ordinary shares would decrease EPS or increase the loss per share from continuing operations. As the Group is loss making there is no difference between the basic and diluted earnings per share. The number of ordinary shares, including potentially dilutive shares is 567,057,257 (2021: 560,836,468). The weighted average number of ordinary shares, including potentially dilutive shares, is 562,689,187 (2021: 474,947,992).

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2022

**5. Intangible assets**

	Software €	Development costs €	Total €
<b>Cost</b>			
At 1 January 2021	208,637	5,213,747	5,422,384
Additions	-	-	-
Foreign exchange translation differences	7,048	-	7,048
<b>At 31 December 2021</b>	<b>215,685</b>	<b>5,213,747</b>	<b>5,429,432</b>
At 1 January 2022	215,685	5,213,747	5,429,432
Foreign exchange translation differences	5,602	-	5,602
<b>At 31 December 2022</b>	<b>221,287</b>	<b>5,213,747</b>	<b>5,435,034</b>
<b>Accumulated amortisation and impairment losses</b>			
At 1 January 2021	208,161	4,514,898	4,723,059
Amortisation	2,666	220,082	222,748
Foreign exchange translation differences	4,858	-	4,858
<b>At 31 December 2021</b>	<b>215,685</b>	<b>4,734,980</b>	<b>4,950,665</b>
At 1 January 2022	215,685	4,734,980	4,950,665
Amortisation	-	213,890	213,890
Foreign exchange translation differences	5,602	-	5,602
<b>At 31 December 2022</b>	<b>221,287</b>	<b>4,948,870</b>	<b>5,170,157</b>
<b>Carrying amount</b>			
At 1 January 2021	476	698,849	699,325
At 31 December 2021	-	478,767	478,767
<b>At 31 December 2022</b>	<b>-</b>	<b>264,877</b>	<b>264,877</b>

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2022

**6. Property, plant and equipment**

	Fixtures, fittings and equipment €	Land and Buildings * €	Total €
<b>Cost</b>			
At 1 January 2021	1,411,587	1,983,647	3,395,234
Additions during the year	65,263	-	65,263
Modification	-	(13,048)	(13,048)
Disposals	-	(24,143)	(24,143)
Foreign exchange translation differences	30,486	56,460	86,946
<b>At 31 December 2021</b>	<b>1,507,336</b>	<b>2,002,916</b>	<b>3,510,252</b>
At 1 January 2022	1,507,336	2,002,916	3,510,252
Additions during the year	44,518	-	44,518
Modification	-	(281,152)	(281,152)
Disposals	(15,794)	-	(15,794)
Foreign exchange translation differences	22,772	47,190	69,962
<b>At 31 December 2022</b>	<b>1,558,832</b>	<b>1,768,954</b>	<b>3,327,786</b>
<b>Depreciation</b>			
At 1 January 2021	1,143,733	601,661	1,745,394
Charge for the year	116,396	344,413	460,809
Disposals	-	(16,870)	(16,870)
Foreign exchange translation differences	23,538	14,496	38,034
<b>At 31 December 2021</b>	<b>1,283,667</b>	<b>943,700</b>	<b>2,227,367</b>
At 1 January 2022	1,283,667	943,700	2,227,367
Charge for the year	92,545	367,468	460,013
Disposals	(9,827)	-	(9,827)
Foreign exchange translation differences	16,568	19,886	36,454
<b>At 31 December 2022</b>	<b>1,382,953</b>	<b>1,331,054</b>	<b>2,714,007</b>
<b>Net book value</b>			
At 1 January 2021	267,854	1,381,986	1,649,840
At 31 December 2021	223,669	1,059,216	1,282,885
<b>At 31 December 2022</b>	<b>175,879</b>	<b>437,900</b>	<b>613,779</b>

\* Land and Buildings is comprised of Right of Use assets, held under leases.

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2022

**7. Trade and other receivables**

	<b>2022</b> <b>Unaudited</b> €	2021 Audited €
<i>Amounts falling due within one year:</i>		
Trade receivables	<b>995,595</b>	809,856
Prepaid expenses and other current assets	<b>1,638,690</b>	998,891
Research and development tax credit	<b>628,224</b>	632,829
Sales tax recoverable	<b>79,654</b>	96,758
	<b>3,342,163</b>	2,538,334
<i>Amounts falling due after more than one year:</i>		
Research and development tax credit	<b>639,639</b>	603,526
	<b>3,981,802</b>	3,141,860

**8. Trade and other payables (current)**

	<b>2022</b> <b>Unaudited</b> €	2021 Audited €
<i>Amounts falling due within one year:</i>		
Trade payables	<b>1,071,692</b>	843,727
Payroll related taxes	<b>151,715</b>	2,750,146
Superannuation / retirement benefit	<b>44,278</b>	41,258
Other payables and accruals	<b>2,469,283</b>	2,773,455
Sales tax payable	<b>74,281</b>	78,924
Deferred income	<b>3,234,186</b>	3,279,125
R&D tax credit – deferred grant income	<b>99,220</b>	119,949
	<b>7,144,655</b>	9,886,584



**Notes to the Preliminary Final Report**  
for the year ended 31 December 2022

**9. Trade and other payables (non-current)**

	<b>2022</b> <b>Unaudited</b> €	2021 Audited €
Payroll related taxes	<b>2,476,858</b>	-
Other payables and accruals	<b>312,779</b>	-
	<hr/> <b>2,789,637</b> <hr/>	<hr/> - <hr/>

**10. Share capital**

<b>Authorised Share Capital</b>	<b>2022</b> <b>Unaudited</b>	2021 Audited
Ordinary shares		
No. of shares	<b>750,000,000</b>	750,000,000
Nominal value	<b>€0.001</b>	€0.001
"B" Ordinary shares		
No. of shares	<b>420,000</b>	420,000
Nominal value	<b>€0.01</b>	€0.01
	<b>€</b>	<b>€</b>
Authorised Ordinary Shares	<b>750,000</b>	750,000
Authorised "B" Ordinary Shares	<b>4,200</b>	4,200
	<hr/>	<hr/>
Authorised Share Capital	<b>754,200</b> <hr/>	754,200 <hr/>

For personal use only

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2022

**10. Share capital (continued)**

Issued share capital	No of ordinary shares	Par value of units	Share Capital	Share premium	Total
<b>Balance at 1 January 2021</b>	<b>394,588,636</b>	<b>€0.001</b>	<b>394,589</b>	<b>106,785,298</b>	<b>107,179,887</b>
Share issue – 5 March 2021	5,275,000	€0.001	5,275	-	5,275
Share issue – 6 April 2021	4,325,000	€0.001	4,325	-	4,325
Exercise of options – 6 April 2021	3,874	€0.001	4	635	639
Share issue – 22 April 2021	6,250,000	€0.001	6,250	-	6,250
Share issue – 22 April 2021	16,666,666	€0.001	16,667	628,745	645,412
Share issue – 4 May 2021	7,824,319	€0.001	7,824	-	7,824
Exercise of options – 2 June 2021	7,498	€0.001	7	1,192	1,199
Share issue – 2 July 2021	300,000	€0.001	300	-	300
Exercise of options – 6 July 2021	100,000	€0.001	100	15,900	16,000
Share issue – 13 Sept 2021	200,000	€0.001	200	-	200
Share issue – 22 Nov 2021	4,255,320	€0.001	4,255	-	4,255
Share issue – 9 Dec 2021	65,019,787	€0.001	65,020	11,088,311	11,153,331
Share issue – 22 Dec 2021	4,606,666	€0.001	4,607	-	4,607
Share issue – 22 Dec 2021	9,054,287	€0.001	9,054	1,551,786	1,560,840
<b>Balance at 31 December 2021</b>	<b>518,477,053</b>	<b>€0.001</b>	<b>518,477</b>	<b>120,071,867</b>	<b>120,590,344</b>
Share issue – 13 Jan 2022	444,444	€0.001	444	-	444
Share issue – 11 Apr 2022	538,989	€0.001	539	-	539
Share issue – 4 May 2022	1,164,757	€0.001	1,165	-	1,165
Share issue – 20 Jun 2022	96,000	€0.001	96	-	96
Share issue – 7 Sept 2022	240,796	€0.001	241	-	241
Share issue – 3 Oct 2022	1,104,107	€0.001	1,104	-	1,104
Share issue – 2 Nov 2022	924,298	€0.001	924	-	924
Exercise of options – 9 Nov 2022	12,000,000	€0.001	12,000	297,458	309,458
<b>Balance at 31 December 2022</b>	<b>534,990,444</b>	<b>€0.001</b>	<b>534,990</b>	<b>120,369,325</b>	<b>120,904,315</b>

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2022

**11. Reconciliation of net cash used in operating activities**

	<b>2022</b>	2021
	<b>Unaudited</b>	Audited
	€	€
<b>Loss for the year</b>	<b>(10,869,459)</b>	(8,185,019)
<i>Non-cash items</i>		
Depreciation	<b>460,013</b>	460,809
Loss on disposal of property, plant and equipment	<b>5,967</b>	-
Amortisation of software and development costs	<b>213,890</b>	222,748
Gain on modification of lease liabilities	<b>(62,610)</b>	-
R&D credit, net	<b>(673,798)</b>	(792,497)
Taxation	<b>(55,221)</b>	56,723
Net finance costs	<b>104,362</b>	118,530
Share based payment expense	<b>2,996,691</b>	1,573,623
Foreign exchange (gain)/loss	<b>57,527</b>	(120,230)
<b>Changes in assets and liabilities</b>		
Increase in inventories	<b>(541,612)</b>	(449,446)
(Increase)/decrease in trade and other receivables	<b>(808,434)</b>	1,390,889
Decrease/(increase) in contract assets	<b>69,431</b>	(60,700)
Decrease in deferred income	<b>(79,208)</b>	(34,106)
(Decrease)/increase in trade and other payables	<b>(228,148)</b>	1,395,443
	<hr/>	<hr/>
<b>Cash used in operating activities</b>	<b>(9,410,609)</b>	(4,423,233)
Finance charges paid	<b>(104,932)</b>	(118,617)
Interest received	<b>570</b>	87
Research and development tax credit received	<b>621,561</b>	638,258
Income tax paid	<b>(16,671)</b>	(123,290)
	<hr/>	<hr/>
<b>Net cash used in operating activities</b>	<b>(8,910,081)</b>	(4,026,795)
	<hr/>	<hr/>



James Fitter  
Chief Executive Officer

Date: 22 February 2023

## Corporate Directory

**Registered office  
and business address**

2<sup>nd</sup> Floor Avoca Court  
Temple Road  
Blackrock  
Co. Dublin  
Ireland

**Independent auditor**

KPMG  
Chartered Accountants  
1 Stokes Place  
St. Stephen's Green  
Dublin 2

**Bankers**

HSBC Bank Limited  
Guildford and Weybridge Commercial Centre  
Edgeborough Road  
Guildford  
Surrey GU12BJ  
United Kingdom

**Solicitors**

A&L Goodbody  
25-28 North Wall Quay  
Dublin 1

Clayton Utz  
Level 15  
1 Bligh Street  
Sydney  
NSW 2000  
Australia

**Company secretary**

Helena D'Arcy

**Registry**

Computershare Investor Services Pty Ltd  
Level 4  
60 Carrington Street  
Sydney  
NSW 2000  
Australia

**Company number**

513842

**ABRN:**

610 611 768

**ASX Code:**

ASX: ONE

**Company Website:**

[www.oneviewhealthcare.com](http://www.oneviewhealthcare.com)

For personal use only